These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18666039)

  • 1. Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea.
    Scheinfeld N; Biggers K
    Curr Opin Investig Drugs; 2008 Aug; 9(8):913-24. PubMed ID: 18666039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.
    Louie TJ; Peppe J; Watt CK; Johnson D; Mohammed R; Dow G; Weiss K; Simon S; John JF; Garber G; Chasan-Taber S; Davidson DM;
    Clin Infect Dis; 2006 Aug; 43(4):411-20. PubMed ID: 16838228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer.
    Weiss K
    Int J Antimicrob Agents; 2009 Jan; 33(1):4-7. PubMed ID: 18804351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile.
    Hinkson PL; Dinardo C; DeCiero D; Klinger JD; Barker RH
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2190-5. PubMed ID: 18391047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties.
    Barker RH; Dagher R; Davidson DM; Marquis JK
    Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1525-34. PubMed ID: 17206941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea.
    Braunlin W; Xu Q; Hook P; Fitzpatrick R; Klinger JD; Burrier R; Kurtz CB
    Biophys J; 2004 Jul; 87(1):534-9. PubMed ID: 15240486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic.
    Johnson AP
    Curr Opin Investig Drugs; 2007 Feb; 8(2):168-73. PubMed ID: 17328233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapies in the treatment of Clostridium difficile-associated disease.
    Jodlowski TZ; Oehler R; Kam LW; Melnychuk I
    Ann Pharmacother; 2006 Dec; 40(12):2164-9. PubMed ID: 17119105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Past, present, and future therapies for Clostridium difficile-associated disease.
    Surowiec D; Kuyumjian AG; Wynd MA; Cicogna CE
    Ann Pharmacother; 2006 Dec; 40(12):2155-63. PubMed ID: 17148650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic.
    Sears P; Ichikawa Y; Ruiz N; Gorbach S
    Ann N Y Acad Sci; 2013 Jul; 1291():33-41. PubMed ID: 23672600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.
    Garey KW; Salazar M; Shah D; Rodrigue R; DuPont HL
    Ann Pharmacother; 2008 Jun; 42(6):827-35. PubMed ID: 18430792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Choice of antibiotics in diarrhea due to Clostridium difficile].
    Andersen IB; Bendtsen F
    Ugeskr Laeger; 1999 Feb; 161(8):1091-4. PubMed ID: 10074847
    [No Abstract]   [Full Text] [Related]  

  • 13. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection.
    Baines SD; Freeman J; Wilcox MH
    Antimicrob Agents Chemother; 2009 May; 53(5):2202-4. PubMed ID: 19223641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic?
    Pepin J
    Clin Infect Dis; 2008 May; 46(10):1493-8. PubMed ID: 18419481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.
    Anton PM; O'Brien M; Kokkotou E; Eisenstein B; Michaelis A; Rothstein D; Paraschos S; Kelly CP; Pothoulakis C
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3975-9. PubMed ID: 15388461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.
    Peppe J; Porzio A; Davidson DM
    Br J Clin Pharmacol; 2008 Jul; 66(1):102-9. PubMed ID: 18341677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mouse model of Clostridium difficile-associated disease.
    Chen X; Katchar K; Goldsmith JD; Nanthakumar N; Cheknis A; Gerding DN; Kelly CP
    Gastroenterology; 2008 Dec; 135(6):1984-92. PubMed ID: 18848941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral vancomycin may have significant absorption in patients with Clostridium difficile colitis.
    Chihara S; Shimizu R; Furukata S; Hoshino K
    Scand J Infect Dis; 2011 Feb; 43(2):149-50. PubMed ID: 20831355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000-2004.
    Barbut F; Gariazzo B; Bonné L; Lalande V; Burghoffer B; Luiuz R; Petit JC
    Infect Control Hosp Epidemiol; 2007 Feb; 28(2):131-9. PubMed ID: 17265393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of Clostridium difficile toward antimicrobial agents used as feed additives for food animals.
    Aarestrup FM; Tvede M
    Microb Drug Resist; 2011 Mar; 17(1):125-7. PubMed ID: 20950192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.